Morgan Stanley analyst Thomas Wrigglesworth initiated coverage of Novonesis (NVZMY) with an Overweight rating and DKK 577 price target Novonesis is a “high-quality biotech-based growth compounder” with structural end market drivers to sustain above-peer sales growth and margins, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVZMY: